Show simple item record

dc.contributor.authorHejazi, ME
dc.contributor.authorShafiifar, A
dc.contributor.authorMashayekhi, S
dc.contributor.authorSattari, M
dc.date.accessioned2018-08-26T08:54:39Z
dc.date.available2018-08-26T08:54:39Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54175
dc.description.abstractBackground: The frequent use of corticosteroid inhalers (CSIs), especially at higher doses, has been accompanied by concern about both systemic and local adverse reactions. The local adverse reactions of inhaled corticosteroids (ICSs) are considered to constitute infrequent and minor problems. However, while not usually serious, these local adverse reactions are of clinical importance. This study assessed the prevalence of local adverse reactions, their clinical features, role of inhaler devices and current measures that have been suggested to prevent the problem. Materials and Methods: This study was performed in YAS clinic in Tabriz on 500 asthmatic patients. A questionnaire about the patients’ demographic information, methods of using CSIs, local care after using CSIs, using spacer devices, doses of ICSs, and adverse reactions were filled then the patients were clinically examined for local adverse reactions. Results: Only 56% patients were using CSIs properly. In general, the incidence of complications was: oropharyngeal candidiasis 25.6%, laryngeal weakness 8.8%, choking 17.6%, tooth decay 15.2%, speechlessness 36.2%, taste decrease 20.8%, tongue burning 29.8% and tongue abrasion 27.8%. Conclusion: Persistent asthma can be effectively controlled with currently available CSIs. Although not life-threatening, local adverse reactions of ICSs are clinically significant and warrant attention. Use of spacer devices and changes in CSI usage, dosage amount and frequency and rinsing and gargling are the methods that have been used to reduce the incidence of local adverse reactions. آ© 2016 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran.
dc.language.isoEnglish
dc.relation.ispartofTanaffos
dc.subjectbeclometasone
dc.subjectcorticosteroid
dc.subjectfluticasone propionate plus salmeterol xinafoate
dc.subjectprednisolone
dc.subjectadolescent
dc.subjectadult
dc.subjectairway obstruction
dc.subjectArticle
dc.subjectasthma
dc.subjectchild
dc.subjectchoking
dc.subjectclinical feature
dc.subjectcontrolled study
dc.subjectdemography
dc.subjectdental caries
dc.subjectdrug dosage form comparison
dc.subjectdrug use
dc.subjectfemale
dc.subjectheart palpitation
dc.subjecthuman
dc.subjectincidence
dc.subjectlaryngeal weakness
dc.subjectlarynx disorder
dc.subjectlarynx weakness
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical information
dc.subjectmetered dose inhaler
dc.subjectmouth hygiene
dc.subjectoropharynx candidiasis
dc.subjectpractice guideline
dc.subjectprophylaxis
dc.subjectschool child
dc.subjectspeech disorder
dc.subjectspeechlessness
dc.subjecttaste disorder
dc.subjectthrush
dc.subjecttongue abrasion
dc.subjecttongue burn
dc.subjecttongue burning
dc.subjecttongue disease
dc.subjecttongur burning
dc.subjecttremor
dc.subjectyoung adult
dc.titleEvaluation of proper usage of glucocorticosteroid inhalers and their adverse effects in asthmatic patients
dc.typeArticle
dc.citation.volume15
dc.citation.issue1
dc.citation.spage9
dc.citation.epage16
dc.citation.indexScopus


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record